HomeAIAI Science & HealthFDA Clears Sine Health App to Monitor Essential Tremor

FDA Clears Sine Health App to Monitor Essential Tremor

The US Food and Drug Administration has cleared a smartphone app from Sine Health as a way for clinicians to monitor essential tremor between appointments. The clearance is a 510(k) decision, recorded as K261026, dated 15 November 2026. It is a monitoring aid, not a diagnosis or a treatment.

Sine Health, which announced the decision in a release on 17 November, said the app “measures tremor passively as patients go about their day, using the sensors already in their smartphone,” and gives clinicians “an objective view of how a patient’s tremor changes between visits.” The company, which issued the release from Stockholm and says it was formerly Nordic Kinetics, likened the app to “a step counter” that “works in the background.” It called Sine “the first FDA-cleared way to monitor essential tremor using only a smartphone.” That “first” claim is Sine’s. The FDA 510(k) record for K261026 lists the device as “Sine Monitoring Essential Tremor Smartphone,” the applicant as Nordic Kinetics AB of Lund, Sweden, a receipt date of 30 March 2026, a decision date of 15 November 2026, a “Substantially Equivalent” outcome, the Neurology panel, and a traditional 510(k). The gap between the receipt date and the decision is about seven and a half months. Substantial equivalence is the standard 510(k) finding. It is not a statement that the app diagnoses essential tremor, or that it treats it. The FDA record, as Research read it, does not itself use the word “first,” and it does not publish a performance table for the new device.

The company says essential tremor “affects about 7 million Americans.” That is Sine’s figure, not an official FDA prevalence count, and it is not independently checked in this article. Jakob Gerstl, Sine Health’s founder and chief executive, said the need to measure how patients “actually do at home is growing” as new therapies arrive. The release does not cite a published accuracy study for the new clearance, and it does not name a predicate device. Those details, if they appear, would be in the FDA record or in a later study, not in the announcement.

Sine also says the decision “follows FDA clearance in June 2026 of Sine Health’s Parkinson’s disease monitoring system using Apple Watches,” and that this is “the company’s second FDA clearance since founding last year.” Those are the company’s statements about an earlier product. They do not change what this clearance is: a smartphone monitoring aid for essential tremor.

Wearable and software tools that watch neurological symptoms between clinic visits are a growing file at TSN. Empatica’s FDA-cleared WellPD system tracks Parkinson’s symptoms at home, a closer cousin than a screening questionnaire. RPI’s Quest2Dx work uses health questionnaires to screen for Parkinson’s, which is a different job — screening, not ongoing monitoring of a diagnosed tremor. A separate FDA clearance for an MRI-based tool that scores breast-cancer recurrence risk is another reminder that a 510(k) can clear a monitoring or risk-scoring aid without turning it into a diagnosis.

A 510(k) monitoring aid is not a diagnosis, and “first” is Sine’s claim

K261026 places Sine’s app in a familiar regulatory category: a device found substantially equivalent to a predicate, cleared so clinicians can use it as a monitoring aid. That is a real clearance, and it is not a licence to diagnose essential tremor, to adjust treatment automatically, or to replace a neurological examination. Nothing in the company’s release, and nothing in the FDA record as Research read it, publishes a sensitivity or error rate for the new app. Until an accuracy study is cited, the claim to an “objective view” of tremor between visits should be read as the company’s description of what the app is for, not as a measured performance result.

The two headline numbers attached to the announcement belong in the same register. “First … using only a smartphone” is Sine’s wording, not a finding in the 510(k) decision letter as summarised here. “About 7 million Americans” is the company’s prevalence figure. Both can be reported as claims without being promoted into facts about the disease or the competitive field. The next things to watch are narrower: whether Sine publishes a validation study, how the app is actually labelled for clinicians, and whether the earlier Parkinson’s clearance and this essential-tremor clearance are used together or remain separate products.

Sources

Related stories

Empatica’s FDA-Cleared WellPD Tracks Parkinson’s Symptoms at Home is the closest recent TSN account of an FDA-cleared tool for watching a movement disorder between clinic visits, and is the next read.

Follow @tsnmediahub on X for breaking AI news as it happens.

Follow on X

Share this story

Latest stories

More in this category

Latest stories

Explore the TSN Atlas: Every topic we cover, mapped. Click a bubble to dive in.